Supported by      

Critical Care Reviews Newsletter

Newsletter 534  |  March 6th 2022

Register for the free weekly newsletter

RePHILL Trial Result Livestream Flyer

RePHILL Trial Results Livestream Monday March 7th, 19:30 UTC+0

Welcome to the 534th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.

The highlights of this week's edition are randomised controlled trials on empagliflozin in patients hospitalized for acute heart failureprophylactic melatonin for delirium in intensive care; systematic reviews and meta analyses on balanced versus unbalanced fluid in critically ill children & the association of tranexamic acid administration with mortality and thromboembolic events in patients with traumatic injury; and observational studies on the association between high-sensitivity troponin I after cardiac surgery and outcomes & decompressive craniectomy practice following traumatic brain injury.

There are also guidelines on candidacy for extracorporeal life support in children after hematopoietic cell transplantation & anesthetic and intensive care management of lung transplantation; narrative reviews on diaphragm-protective mechanical ventilation & renal compression in heart failure; and editorials on ten myths about albumin & timing for initiating renal replacement therapy in patients with acute kidney injury; as well as correspondence on liberal versus conservative fluid therapy in COVID-19 patients & Russian doctors, nurses, and paramedics demand an end to hostilities in Ukraine

If you only have time to read one review article this week, try this one on how much underfeeding can the critically ill adult patient tolerate?.

Critical Care Reviews Meeting 2022

Today, we've crossed the 100 day threshold to CCR22. Registration is open for our 10th meeting, on June 15th to 17th at Titanic Belfast.

RePHILL Trial Results Livestream

We will be bringing you the results of the randomised controlled RePHILL trial, on Monday March 7th. RePHILL investigates whether pre-hospital blood product resuscitation, with up to two units each of packed red blood cells and lyophilised plasma, will improve tissue perfusion (as measured by lactate clearance) and reduce mortality in trauma patients with haemorrhagic shock, compared to the current standard practice of crystalloid (normal saline) resuscitation. The livestream starts at 19:30 UTC+0 and is free to view. 1.5 CPD points will be available for a small charge.

I hope you find this newsletter useful.


Until next week

Rob

 

Supported by

My Intensive Care Logo

 

 

 

 

Promoting Open Access to Scientific Advancement
Supported by      


© All rights reserved.

Back to Top